Goldman Sachs lowered estimates on Impax Laboratories (NASDAQ: IPXL) Friday morning in order to account for "the impact from Actavis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE